期刊名称：JOURNAL OF IMMUNOLOGICAL METHODS
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
|
The Journal of Immunological Methods is devoted to covering techniques for: (1) Quantitating and detecting antibodies and/or antigens and haptens based on antigen-antibody interactions. (2) Fractionating and purifying immunoglobulins, lymphokines and other molecules of the immune system. (3) Isolating antigens and other substances important in immunological processes. (4) Labelling antigens and antibodies with radioactive and other markers. (5) Localizing antigens and/or antibodies in tissues and cells, in vivo or in vitro. (6) Detecting, enumerating and fractionating immunocompetent cells. (7) Assaying for cellular immunity. (8) Detecting cell-surface antigens by cell-cell interactions. (9) Initiating immunity and unresponsiveness. (10) Transplanting tissues. (11) Studying items closely related to immunity such as complement, reticuloendothelial system and others.
In addition the journal will publish articles on novel methods for analysing the organization, structure and expression of genes for immunologically important molecules such as immunoglobulins, T cell receptors and accessory molecules involved in antigen recognition, processing and presentation. Submitted full length manuscripts should describe new methods of broad applicability to immunology and not simply the application of an established method to a particular substance - although papers describing such applications may be considered for publication as a short Technical Note
The Recombinant Technology section will contain articles relating to modification by recombinant techniques of molecules of immunological interest; isolation of novel binding proteins by phage display; gene therapy; transfection; and expression.
Immunology Protocols is a section providing detailed, step-by-step descriptions of new and established techniques in immunology. Articles on the molecular biological analysis of immunologically relevant receptor binding sites are also invited.
|
|
Instructions to Authors
There are different Instructions to Authors for authors submitting a Protocol-(click here); these are also to be found in J. Immunol. Meth. Vol. 226(1999)1-2.
Submission of a paper to the Journal of Immunological Methods is understood to imply that it has not previously been published and that it is not being considered for publication elsewhere. It will also be assumed that submission has the approval of all the authors. The preferred medium of final submission to the accepting editor is on disk with the accompanying reviewed and revised manuscript (see 'electronic manuscripts' below).
Manuscripts (other than a Protocol) should be addressed to either Editor in Chief:
M.C. Nussenzweig, The Rockefeller University, 1230 York Avenue, New York, NY 10021-6399, USA. E-mail:nussen@rockvax.rockefeller.edu or
M.W. Turner, Immunobiology Unit, Institute of Child Health, University of London, 30 Guilford Street, London WC1N 1EH, UK . E-mail: m.turner@ich.ucl.ac.uk
Immunology Protocols only, should be sent to the Section Editor:
A.R. Mire-Sluis, Principal Advisor for Regulatory Science and Review, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, Rm 3082, HFD-3, 1451 Rockville Pike, Rockville, MD 20852. E-mail: mire-sluisa@cder.fda.gov; Fax: +301-594-2503
In the event of rejection manuscripts will be retained in the Editorial Office for 3 months so that authors may request the return of any original material. Unclaimed material will be discarded after this time.
Informed consent
Investigations on human subjects must include a statement indicating that informed consent was obtained after the nature and possible consequences of the studies had been fully explained.
Animal welfare
Authors using experimental animals must state that their care was in accordance with institutional guidelines. For animals subjected to invasive procedures, the anesthetic, analgesic and tranquilizing agents used, as well as the amounts and frequency of administration, must be stated.
Availability of Materials
Publication of an article in the Journal of Immunological Methods is taken to imply that the authors are prepared to freely distribute materials used in the published experiments (e.g. antibodies, cell lines) to academic researchers for their own use.
Types of papers
Review-type articles on methods, including their development, applicability and present status, usually invited by an editor; research reports, full-length articles describing original work; technical notes (short communications and application notes, being 4 pages of type plus up to 10 references and 2-3 display items); letters to the editors - in order to expedite publication of the letters no proofs will be sent to the authors; book reviews and Software Notices (see later). News and announcements are welcomed. Authors wishing to submit articles of any of these types but relating to Recombinant Technology should follow the same Instructions but submit their material directly to the Section Editor above. Authors wishing to submit a Protocol are directed to the separate Notes to Authors for Protocols, to be found here (click) or in J. Immunol. Meth. Vol. 226 (1999)1-2.
Suggestions for potential reviewers
Authors are invited to provide the names, addresses and (if possible) fax numbers and e-mail addresses of up to six potential reviewers. It would not be appropriate to nominate individuals that have had any input into the manuscripts submitted or any recent collaboration with the authors. The Editors may or may not take these suggestions into account during the reviewing process.
Preparation of the text
To avoid unnecessary delays authors should adhere strictly to the following instructions.
Manuscripts should be accompanied by a title page and an abstract. In order to expedite publication the original and three copies (also of figures) are required.
Manuscripts should be typewritten with double spacing and wide margins. Words to be printed in 'italics' should be underlined. The metric system is to be used throughout. Authors in Japan please note: Upon request, Elsevier Science Japan will provide authors with a list of people who can check and improve the English of their paper (before submission). Please contact our Tokyo office: Elsevier Science K.K., 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044; Tel. (03)-5561-5032; Fax: (03)-5561-5045.
Electronic manuscripts
Electronic manuscripts have the advantage that there is no need for the rekeying of text, thereby avoiding the possibility of introducing errors and resulting in reliable and fast delivery of proofs.
The preferred storage medium is a 5 1/4 or 31/2 inch disk in MS-DOS format, although other systems are welcome, e.g., Macintosh (in this case, save your file in the usual manner, do not use the option 'save in MS-DOS format'); if you use NEC, please submit your article on a double density or high density 51/4 inch disk or double density 31/2 inch disk (not a high density 31/2 inch disk). Please do not split the article into seperate files (title page as one file, text as another, etc.). Ensure that the letter 'l' and digit '1' (also letter 'O' and digit '0') have been used properly, and structure your article (tabs, indents, etc.) consistently. Characters not available on your wordprocessor (Greek letters, mathematical symbols, etc.) should not be left open but indicated by a unique code (e.g., gralpha, @, #, etc., for the Greek letter ). Such codes should be used consistently throughout the entire text. Please make a list of such codes and provide a key. Do not allow your wordprocessor to introduce word splits and do not use a 'justified' layout. Please adhere strictly to the general instructions on style/arrangement and, in particular, the reference style of the journal. It is very important that you save your file in the wordprocessor format. If your wordprocessor features the option to save files 'in flat ASCII', please do not use it. Format your disk correctly and ensure that only the relevant file (one complete article only) is on the disk. Also, specify the type of computer and wordprocessing package used and label the disk with your name and the name of the file on the disk. After final acceptance, your disk plus one, final, printed and exactly matching version (as a printout) should be submitted together to the accepting editor. It is important that the file on disk and the printout are identical. Both will then be forwarded by the editor to Elsevier. Further information may be obtained from the Publisher.
Title page
The title page should be a separate sheet, and should include: the title, the name(s) of the author(s), their affiliations, a footnote indicating the author to whom correspondence and proofs should be sent stating her/his full address, telephone and fax numbers and e-mail address, and a footnote providing the abbreviations used in the paper.
Abstract
The abstract, not more than 5% of the length of the article, should be on a separate sheet. It will appear at the beginning of the paper.
Key words
Key words should be provided at the foot of the abstract. Normally 3-6 items should be included.
Instructions regarding GenBank/DNA sequence linking.
DNA sequences and GenBank Accession numbers
Many Elsevier journals cite "gene accession numbers" in their running text and footnotes. Gene accession numbers refer to genes or DNA sequences about which further information can be found in the database at the National Center for Biotechnical Information (NCBI) at the National Library of Medicine. Elsevier authors wishing to enable other scientists to use the accession numbers cited in their papers via links to these sources, should type this information in the following manner":
For each and every accession number cited in an article, authors should type the accession number in bold, underlined text. Letters in the accession number should always be capitalised. (See Example 1 below). This combination of letters and format will enable Elsevier's typesetters to recognize the relevant texts as accession numbers and add the required link to GenBank's sequences.
Example 1: "GenBank accession nos. AI631510, AI631511, AI632198, and BF223228, a B-cell tumor from a chronic lymphatic leukemia (GenBank accession no. BE675048, and a T-cell lymphoma (GenBank accession no. AA361117)".
Authors are encouraged to check accession numbers used very carefully. An error in a letter or number can result in a dead link.
In the final version of the printed article, the accession number text will not appear bold or underlined (see Example 2 below).
Example 2: "GenBank accession nos. AI631510, AI631511, AI632198, and BF223228), a B-cell tumor from a chronic lymphatic leukemia (GenBank accession no. BE675048), and a T-cell lymphoma (GenBank accession no. AA361117)".
In the final version of the electronic copy, the accession number text will be linked to the appropriate source in the NCBI databases enabling readers to go directly to that source from the article (see Example 3 below).
Example 3: "GenBank accession nos. AI631510, AI631511, AI632198, and BF223228), a B-cell tumor from a chronic lymphatic leukema (GenBank accession no. BE675048), and a T-cell lymphoma (GenBank accession no. AA361117)".
References
References in the text start with the name of the author(s), followed by the publication date in brackets, e.g.: 'Larsson (1988) has shown the importance of ...', or , '... has been described (Larsson, 1988; Anderson et al., 1996)...', using date order.
The references in the reference list should be in alphabetical order and typed double-spaced on sheets separate from the text.
References to journals should contain names and initials of the author(s), year of publication (between brackets), article title, abbreviation of the name of the journal according to the List of Serial Title Word Abbreviations (International Serials Data System, 20, rue Bachaumont, 75002 Paris, France. ISBN 2-904938-02-8), volume number and pagenumber. References to books should also include the title (of series and volume), initials and names of the editor(s) and, between brackets, publisher and place of publication. Periodicals, books and multi-author books should accord with the following examples:
Examples
Anderson, W.H., Davidson, T.M. and Broide, D.H., 1996.
Mast cell TNF mRNA expression in nasal mucosa demonstrated by in situ hybridization: a comparison of mast cell detection methods. J. Immunol. Methods 189, 145.
Larsson, L.-I., 1988. Immunocytochemistry: Theory and Practice.
CRC Press, Boca Raton, FL.
Modrow, S., and Wolf, H., 1990. Use of synthetic peptides as diagnostic reagents in virology. In: M.H.V. Van Regenmortel and A.R. Neurath (Eds.) Immunochemistry of Viruses II: The basis for serodiagnosis and vaccines. Elsevier, Amsterdam, p.83.
Tables and figures Tables should be compiled on separate sheets and numbered in Roman numerals.
Four sets of figures are to be submitted. At least one set must be of publication quality and the other three sets must be clear enough to be useful to the referees. Figures should be completely lettered, the size of the lettering being appropriate, taking into account the necessary reduction in size (preferably not more than one third). The page format should be considered in designing the figures. The figures should be numbered in Arabic numerals.
Photographs must be of good quality, printed on glossy paper. Photocopies of photomicrographs are not acceptable. Colour photographs are accepted on the recommendation of the Editor at no charge to the author.
Tables, figures and photographs should be clearly marked on the reverse side with the number, author's name and orientation (top); use a soft pencil or preferably a felt-tipped pen for marking photographs. Legends should be supplied on separate sheets.
Software notices and on-line Computational Modeling section.
(1) Software submitted to this section must be noncommercial and of use to immunologic laboratories. It should involve methods of data analysis and/or visualization, or utilize a novel approach to techniques within the scope of the Journal of Immunological Methods.
(2) By submitting software, the authors agree to allow unlimited distribution of the software and documentation, if accepted. Actual distribution is coordinated through the software notice editor. A directory of available software will be listed periodically in the journal, and updates submitted by the original authors will be automatically added to the directory.
(3) Submission of software to be considered in the software notice section is to be made directly to the software notice editor, Stephen J. Merrill, Department of Mathematics, Statistics and Computer Science, Marquette University, P.O. Box 1881, Milwaukee, WI 53201-1881, USA, E-mail:stevem@jim.mscs.mu.edu and should consist of:
(i) two copies of the source code and/or binaries (compiled version);
(ii) one printed and one machine-readable (disk) version of the documentation;
(iii) a 1-2 page description of the software including the following: title of the software package, primary purpose, type of computer, hardware/memory requirements, a short example illustrating its use, and all necessary references. The actual `notice' will be an edited version of this description. The description should be looked on as an item which may be referenced in other papers.
(4) The software, documentation, and description will be quickly reviewed and tested with special attention to completeness of the documentation and ease of use. Necessary revisions will be communicated to the authors by the section editor.
In order to access the Software Archive refer to the Journal of Immunological Methods, 153 (1992) 5-6.
Computational Modeling
Articles dealing with the uses of computers and modeling techniques in facilitating immunological research, and appropriate for on-line publication, may also be sent to Dr. Merrill (see 3 above) as submissions for the Computational Modeling section of the Journal of Immunological Methods web site (http://www.elsevier.nl/locate/jimweb).
Proofs and reprints
One set of proofs will be supplied for the author to check for type-setting accuracy. No changes to the original manuscript will be allowed at this stage.
Each author receives, with his proofs, a reprint order form, which he is asked to complete and return to Journal of Immunological Methods, Log-in Department, Elsevier Science Ireland Ltd, Elsevier House, Brookvale Plaza, East Plaza, Shannon, Co. Clare, Ireland, together with the proofs and the copyright transfer form (if applicable). 50 reprints are provided free of charge. There will be no page charge.
Protocols.
On acceptance of a submitted protocol, it will first appear in the Protocols section of the Journal of Immunological Methods Web site (http://www.elsevier.nl/locate/jimweb). The Protocol will also appear in the next available issue of the printed journal, at which time the electronic version of the Protocol will move into the Protocol Archive section of the Web site.
Manuscripts
Submission of a Protocol to the Journal of Immunological Methods is understood to imply that it has not previously been published and that it is not being considered for publication elsewhere. It will also be assumed that the submission has the approval of all of the listed authors. Submission should be addressed to:
A.R. Mire-Sluis, Executive Director Analytical Sciences, CancerVax Corporation, 5931 Darwin Court, Carlsbad, CA 92008, USA. E-mail: tms@cancervax.com
The medium of final submission is on disk with accompanying revised manuscript (see "Electronic manuscripts" below). Manuscripts should be written in English and be accompanied by an abstract, theme, topic, and 3-6 key words on a separate page. As well as the disk copy, four print-out copies of each manuscript should be submitted in double-spaced typing with at least a 4 cm margin on numbered pages of uniform size. Protocols should be divided into numbered sections headed by a caption (Abstract; 1. Type of research; 2. Time required; 3. Materials; 4. Detailed procedure; 5. Results; 6. Discussion; 7. Essential references; 8. References; 9. Quick procedure). The order of subdivision within sections is as follows: Arabic numerals (e.g. 3.1.), lower case roman characters (a, b etc.). Listings should be indicated by dashes. In order to ensure timely publication, no revisions or up-dating will be incorporated after the manuscript has been accepted and sent to the Publisher. Please note that the past tense is not to be used in writing a Protocol.
Electronic manuscripts. Electronic manuscripts have several advantages: there is no need for the re-keying of text, thereby avoiding the possibility of introducing errors and resulting in reliable and fast delivery of proofs. The preferred storage medium is a 3.5 inch disk in MS-DOS format, although other systems are also supported, e.g. NEC and Macintosh (in the latter case, save your file in the usual manner, do not use the option "save in MS-DOS format"). After final acceptance, your disk plus one final, printed and exactly matching version (as a printout) should be submitted together to the Editor. It is important that the file on disk and the printout are identical. Please specify the type of computer and word processing package used (do not convert your text file to plain ASCII). Ensure that the letter "l" and the digit "1" (also letter "O" and digit "0") have been used properly, and format your article (tabs, indents, etc.) consistently. Characters not available on your word processor (Greek letters, mathematical symbols, etc.) should not be left open, but indicated by a unique code (e.g. gralpha, @, #, etc. for the Greek letter a). Such codes should be used consistently throughout the entire text. Please make a list of such codes and provide a key. Do not allow your word processor to introduce word splits and do not use a "justified" lay-out. Please adhere strictly to the general instructions on styles/arrangement and, in particular, the reference style of the journal. Tables and illustrations will be handled conventionally; the latter should be submitted as original drawings or glossy prints. Further information may be obtained from the publisher.
Animal welfare
Authors using experimental animals must state that their care was in accordance with institutional guidelines. For animals subjected to invasive procedures, the anesthetic, analgesic and tranquilizing agents used, as well as the amounts and frequency of administration, must be stated.
Availability of materials.
Publication of an article in the Journal of Immunological Methods is taken to imply that the authors are prepared to freely distribute materials used in the published experiments (e.g. antibodies, cell lines) to academic researchers for their own use.
Organization of a Protocol
Title page. The title page should contain the following items: (i) complete title (preferably no chemical formulas or arbitrary abbreviations); (ii) full names of all authors; (iii) complete affiliations of all authors; (iv) the number of text pages of the whole manuscript (including figures and tables) and the number of figures and tables; (v) the name and complete address of the corresponding author to whom proofs should be sent (including telephone number, facsimile number and e-mail address); (vi) acknowledgements. A list of any abbreviations used should be provided as a separate footnote.
Abstract. This should provide a concise description of the purpose of the Protocol and should not exceed 200 words.
Keywords. Please provide 3-6 keywords.
1.Type of research. In this section, relevant published studies should be described concisely in list form preceded by roman lower case numeral characters. The published studies should be appropriately cited.
2. Time required. An estimation of the time required to run the protocol should be given per separate step and for the whole protocol.
3. Materials. The materials to be used should be described in sufficient detail for the protocol to be replicated. Animal information should include: breed, breeder, sex, age, weight and the maintenance conditions. Furthermore, this section should include sub-sections on: (i) Special equipment and (ii) Chemicals and reagents. Any special equipment required should be mentioned, including details of model type/number. The source or supplier of special equipment should also be stated, in parentheses (and with full addresses), after mentioning the equipment for the first time. A listing (preceded by dashes) of chemicals and reagents used should be provided, with their sources or suppliers (with full addresses). For drugs, generic names should be used; trade names may be given in brackets where the drug is first mentioned. In the case of new drugs or chemicals, a full chemical description (formula) should be given. The form of the drug used should be indicated.
4. Detailed procedure. This section should include an extensive, detailed and stepwise description of the procedures to be used. The individual steps should be described as a list of instructions preceded by roman lower case numeral characters and correspond with the steps described under "Quick procedure".
5. Results. In this section the expected results should be described clearly and concisely, and in logical order without extended discussion of their significance. If necessary for clarity, the results can be supplemented by photographs or diagrams.
6. Discussion. This section should present an assessment of the protocol, problems which may be encountered, and alternative or support protocols. This section should be divided into two parts: (i) Trouble-shooting and (ii) Alternative and Support Protocols. Trouble-shooting: Problems that may have been encountered during any of the procedures should be discussed concisely, and solutions suggested. Alternative methods for replacing steps in the protocol should be mentioned in sufficient detail, accompanied by appropriate citation of the literature. If appropriate support protocols should be mentioned.
7. Essential literature references. This should mention certain essential reading divided into original papers, book chapters and review papers. Do not cite the full reference, but just list the authors and year. The total number of references in this section should not exceed 10.
8. Literature references. Citation of literature references in the text should be given at the appropriate places using name and year (Harvard System). More than one paper from the same author in the same year must be identified by the letters a, b, c, etc, placed after the year of publication. In the text, when referring to a work by more than two authors, the name of the first author should be followed by et al. All references cited in the text should be listed at the end of the manuscript on a separate page (also double-spaced) arranged in alphabetical order by first author. They should consist of names and initials of all authors, year of publication (in brackets), title of paper referred to, abbreviated title of periodical, volume number and page number of the paper. The abbreviations of journal titles should conform to those adopted by List of Serial Title Word Abbreviations, CIEPS/ISDS, Paris, 1985 (ISBN 2-904938-02-8). References to books should also include the title (of series and volume), initials and names of the editor(s) and, between brackets, publisher and place of publication. Periodicals, books and multi-author books should accord with the following examples:
Examples:
Anderson, W.H., Davidson, T.M. and Broide, D.H. (1996) Mast cell TNF mRNA expression in nasal mucosa demonstrated by in situ hybridization: a comparison of mast cell detection methods. J. Immunol. Methods 189, 145. Larsson, L.-I. (1988) Immunocytochemistry: Theory and Practice. CRC Press, Boca Raton, FL.
Modrow, S. and Wolf, H. (1990) Use of synthetic peptides as diagnostic reagents in virology. In: M.H.V. Van Regenmortel and A.R. Neurath (Eds.) Immunochemistry of Viruses II: The basis for serodiagnosis and vaccines. Elsevier, Amsterdam, p. 83.
This journal should be cited in lists as J. Immunol. Methods with the prefix capital "P" being added to the page numbers. Should you wish to cite the Protocol before the printed reference is available, please cite an article as: Authors, Year, Title, J.Immunol. Methods Website, Protocol "x" (being the number in the list).
9. Quick procedure. This section should describe the protocol in a concise, stepwise manner. The individual steps should be described in list form preceded by roman lower case numeral characters and correspond with the steps described under Detailed procedure. This section should contain basic, essential information for the protocol to be replicated successfully.
Illustrations
All illustrations must be submitted in quadruplicate as unmounted glossy photographs and reach the Editor in a form and condition suitable for reproduction. If figures are not to be reduced in size their format should not exceed 13.0-20 cm. Lettering should be clear and of adequate size to be legible after reduction (2-6 mm). Professional lettering is preferred, but if this is not possible, an overlay displaying the desired labelling should be provided with the figures. Please note that so-called press-on lettering should be avoided since this is likely to get damaged during handling and photographic processing of the prints. Slides taken from labelled prints are also acceptable. The illustrations should bear the author's name, the orientation (top, bottom etc.) and be numbered in Arabic numerals according to the sequence of appearance in the text, where they are referred to as Fig. 1, Fig. 2, etc. Line drawings should be in black ink on drawing or tracing paper or glossy sharp photographs of the same. Photographs should be supplied as clear black-and-white prints on glossy paper, rather than copies which reproduce detail badly. Micrographs should have a scale bar, rather than a magnification factor, in the legend. The degree of reduction will be determined by the Publisher, but in general it should be assumed that the same degree of reduction will be applied to all figures in the same paper. If illustrations or other small parts of articles or books already published elsewhere are used in papers submitted to Immunology Protocols, the written permission of author and publisher concerned must be included with the manuscript. The original source must be indicated in the legend of the illustration in these cases.
Colour reproduction. Reproduction in colour in print, if approved by the Editor, will be free of charge to the author(s). Colour figures should be submitted as separate prints and not be mounted on cardboard.
Figure Legends. Each illustration must have a title and an explanatory legend. The title should be part of the legend and not be reproduced on the figure itself. The legends should be typed with double-spacing on a separate page at the end of the manuscript and begin with the number of the illustration they refer to. All symbols and abbreviations used in the Figure must be explained.
Tables
Tables should be so constructed that they, together with their captions and legends, will be intelligible with minimal reference to the text. Tables of numerical data should each be typed (also with double-spacing) on a separate page, numbered in sequence in Arabic numerals (Table 1, 2, etc.) and referred to in the text as Table 1, Table 2, etc. The title of the Table should appear above the Table. A detailed description of its contents and footnotes should be given below the body of the Table (identified with a, b, c, etc.).
Proofs
Authors should keep a copy of their manuscripts as proofs will be sent to them without the manuscript. Proofs will usually be drawn on lower quality paper. Only printer's errors may be corrected. No change in, or additions to, the edited manuscript will be allowed at this stage. The author proofs must be returned within 48 hours after receipt, preferably by FAX or electronic mail to facilitate speedy publication. If the Publisher receives no reply after approximately 15 days, the assumption will be made that there are no errors to correct and the article will be published.
Authors can keep track of the progress of their accepted article, and set up e-mail alerts informing them of changes to their manuscript's status, by using the "Track a Paper" feature of Elsevier's Author Gateway.
Reprints
A total of 25 reprints of each paper will be provided free of charge to the author(s). Additional copies can be ordered at prices shown on the reprint order form which will be sent to the author upon receipt of the accepted manuscript at Elsevier.
Page charge
There will be no page charge for Journal of Immunological Methods Protocols.
ELSEVIER Last update: 05 Dec 1999  Copyright 1999, Elsevier Science, All rights reserved.
Editorial Board
-
- Editors:
- M.C. Nussenzweig, The Rockefeller University, 1230 York Avenue, New York, NY 10021-6399, U.S.A. Tel: +1 212 327-8067, Fax: +1 212 327-8370, Email: nussen@rockvax.rockefeller.edu
M.W. Turner, Immunobiology Unit, Institute of Child Health, University of London, 30 Guilford Street, London WC1N 1EH, UK. Tel: +44 207 829 8844, Fax: +44 207 813 8494, Email: m.turner@ich.ucl.ac.uk
- Immunology Protocols Editors:
- T. Mire-Sluis, Principal Advisor for Regulatory Science and Review, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, 1451 Rockville Pike, Rm 3082, HFD-3, Rockville, MD 20852-1448, USA Tel: +1 301-594-2503, Fax: +1 301-594-5614, Email: mire-sluisa@cder.fda.gov
- Software Notice and Computational Modelling Editor:
- S.J. Merrill, Department of Mathematics, Statistics and Computer Science, Marquette University, P.O. Box 1881, Milwaukee, WI 53201-1881, USA. Tel: +1 414 288 7573, Fax: +1 414 288 5472, Email: stevem@jim.mscs.mu.edu
- Editors Emeritus:
- J.R. Battisto
F. Borek
- Editorial Board:
- C.R. Alving, Washington DC, USA
R.S. Basch, New York, NY, USA
L. Bignold, Adelaide, SA, Australia
P. Bongrand, Marseille, France
N. Borregaard, Copenhagen, Denmark
P. Brandtzaeg, Oslo, Norway
K.A. Brown, London, UK
J. Burnie, Manchester, UK
J.D. Capra, Oklahoma City, OK, USA
S. Challacombe, London, UK
E. Claasen, Lelystad, The Netherlands
N.R. Cooper, La Jolla, CA, USA
B. Diamond, New York, NY, USA
C.A. Dinarello, Denver, CO, USA
J. Fabre, London, UK
A.J.T. George, Department of Immunology, Division of Medicine, Imperial College School of Medicine, Hammersmith Hospital, London W122 ONN, UK
J. Goding, Parkville, VIC, Australia
J. Greenman, Hull, UK
J-L. Guesdon, Paris, France
H.R.J.M. Hoogenboom, Maastricht, The Netherlands
P. Hudson, Parkville, Victoria, Australia
J. Huston, Lexington, MA, USA
R. Jefferis, Birmingham, UK
J.C. Jensenius, Århus, Denmark
A.P. Johnstone, London, UK
M. Kazatchkine, Paris, France
T. Kinoshita, Osaka, Japan
H. Koprowski, Philadelphia, PA, USA
J. Laman, Rotterdam, The Netherlands
M. Lamm, Cleveland, OH, USA
R.G. Leslie, Odense, Denmark
R.N. Maini, London, UK
J.L. Maryanski, Lyon, France
L. McPhail, Winston-Salem, NC, USA
A. Meager, Potters Bar, UK
P. Minor, Potters Bar, UK
S.L. Morrison, Los Angeles, CA, USA
E. Nardin, New York, NY, USA
D.J. Newman, Carshalton, UK
J.J. Oppenheim, Frederick, MD, USA
M.G. Ormerod, Charlestown, MA, USA
T. Out, Amsterdam, The Netherlands
E. Pure, Philadelphia, PA, USA
K.B.M. Reid, Oxford, UK
S.J. Rodda, Victoria, Australia
P. Rubinstein, New York, NY, USA
J. Saklatvala, Hammersmith, London, UK
A.W. Segal, London, UK
C.H. Self, Newcastle-upon-Tyne, UK
E.M. Shevach, Bethesda, MD, USA
F. Sinigaglia, Milan, Italy
N. Staines, London, UK
R. Steinman, New York, NY, USA
C.R. Stokes, Avon, UK
D. Stollar, Boston, MA, USA
D. Stott, Glasgow, UK
R.C. Thorpe, Potters Bar, UK
J.C. Unkless, New York, USA
M. van Regenmortel, Strasbourg, France
J. Vilcek, New York, NY, USA
J.W.M. Visser, New York, NY, USA
A. Voller, Berkhamsted, UK
B. Walker, South Mimms, Potters Bar, UK
J.R. Yannelli, Lexington, KY, USA
F. Zavala, New York, NY, USA
H. Zola, North Adelaide, SA, Australia
S.B. Zolla-Pazner, New York, NY, USA
|
